Trial Profile
A Phase II Evaluation of Brivanib (BMS582664, IND105029), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Brivanib alaninate (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- 02 Oct 2017 Status changed from active, no longer recruiting to completed.
- 20 Sep 2013 Planned end date changed from 1 Jan 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 18 Jul 2012 Planned End Date changed from 1 Apr 2011 to 1 Jan 2013 as reported by ClinicalTrials.gov.